Multivariate analysis of predictive factors for PFS in patients with non‐small cell lung cancers who received atezolizumab in combination with bevacizumab, carboplatin or cisplatin and pemetrexed after failure of EGFR tyrosine kinase inhibitors. The gene discussed is EGFR; the disease is lung cancer.